Common diplotypesb | Expected population frequency, %c | PK/PD phenotype | Clinical phenotype | FDA guidelines | ||
---|---|---|---|---|---|---|
Caucasian ancestry | African an cestry | East Asian ancestry | ||||
SLCO1B1*1/*1 | 64 | 92 | 79 | Normal drug transport | Normal response and risk of adverse drug reactions to simvastatin | 80Â mg simvastatin maximum dose |
SLCO1B1*1/V174A, SLCO1B1*1/*6, and another rare diplotype, SLCO1B1*1/*3 | 32 | 8 | 20 | Intermediate decreased drug transport | Intermediate increase in risk of myopathy from simvastatin | 40Â mg simvastatin maximum dose |
SLCO1B1 V174A/V174A, SLCO1B1*6/V174A, and other rare diplotypes (see Additional file 1: Table S28) | 4 | <1 | 1 | Decreased drug transport | Increased risk of myopathy from simvastatin | 20Â mg simvastatin maximum dose |